Is there a benefit on survival of tyrosine-kinase inhibitors versus chemotherapy in first line in mutated EGFR patients with advanced non-small cell cancer (NSCLC)? A meta-analysis.
Gaetan Des Guetz
No relevant relationships to disclose
Bernard Uzzan
No relevant relationships to disclose
Kader Chouahnia
No relevant relationships to disclose
Patrick Nicolas
No relevant relationships to disclose
Jean F. Morere
No relevant relationships to disclose